Alice O Silva(kamphorst), PhD
About Me
Alice O. Kamphorst, PhD is an Assistant Professor of Oncological Sciences at the Precision Immunology Institute. She is also a member of the Cancer Immunology Research Program at the Tisch Cancer Institute.
The Kamphorst lab focuses on T cell differentiation with a specific interest on situations of chronic antigen stimulation, such as in cancer. The research program aims to determine how inflammation, costimulation and other factors in the microenvironment influence CD8 T cell differentiation, dysfunction and rescue by immunotherapy. We study the interplay of different signaling pathways with the PD-1 (programmed cell death-1) pathway. To address those questions the lab uses mouse models of chronic viral infection and tumor, as well as analysis of samples from cancer patients.
Language
English
Position
ASSOCIATE PROFESSOR | Immunology & Immunotherapy, ASSOCIATE PROFESSOR | Oncological Sciences
Research Topics
Anti-Tumor Therapy, Immunology, Infectious Disease, Inflammation, Liver, Lymphocytes, T Cells, Translational Research, Viruses and Virology
Multi-Disciplinary Training Areas
Cancer Biology [CAB], Immunology [IMM]
Education
PhD, Rockefeller University
Postdoc, Emory University
Research
The Kamphorst lab focuses on T cell differentiation with a specific interest on situations of chronic antigen stimulation, such as in cancer. The research program aims to determine how inflammation, costimulation and other factors in the microenvironment influence CD8 T cell differentiation, dysfunction and rescue by immunotherapy. We study the interplay of different signaling pathways with the PD-1 (programmed cell death-1) pathway. To address those questions the lab uses mouse models of chronic viral infection and tumor, as well as analysis of samples from cancer patients. The lab has a deep interest on how adaptive immune responses are modulated and on interventional strategies that can be used to improve human health. Understanding the factors that govern T cell differentiation and function will enable the identification of targetable molecules and pathways to improve the efficacy of immunotherapy.